Roche: Tecentriq wins EU approval for breast cancer
(CercleFinance.com) - Swiss drugmaker Roche said on Thursday that it has received European Commission approval for Tecentriq to treat people with triple-negative breast cancer, an aggressive and difficult-to-treat disease.
The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for this specific kind of cancer, the Basel-based group said.
Immunotherapy is an innovative treatment option that helps a person's own immune system fight cancer.
The European Commission has approved Tecentriq plus chemotherapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression and who have not received prior chemotherapy.
Tecentriq is approved in the US and EU - either alone or in combination with targeted therapies and/or chemotherapies in various forms of cancers, including lung cancer.
Today, Roche also announced the launch of its Ventana assay on European markets as a diagnostic tool to identify triple-negative breast cancer patients eligible for treatment with Tecentriq.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for this specific kind of cancer, the Basel-based group said.
Immunotherapy is an innovative treatment option that helps a person's own immune system fight cancer.
The European Commission has approved Tecentriq plus chemotherapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression and who have not received prior chemotherapy.
Tecentriq is approved in the US and EU - either alone or in combination with targeted therapies and/or chemotherapies in various forms of cancers, including lung cancer.
Today, Roche also announced the launch of its Ventana assay on European markets as a diagnostic tool to identify triple-negative breast cancer patients eligible for treatment with Tecentriq.
Copyright (c) 2019 CercleFinance.com. All rights reserved.